2002 Fiscal Year Final Research Report Summary
Research for the pathogenesis and treatment of Crow-Fukase syndrome
| Project/Area Number |
11470147
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
ARIMURA Kimiyoshi Kagoshima University, Graduate School of Medicine and Dental Sciences, Associate Professor, 大学院・医歯学総合研究科, 助教授 (20159510)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HASHIGUCHI Teruto Kagoshima University, Graduate School of Medicine and Dental Sciences, Associate Professor, 大学院・医歯学総合研究科, 助教授 (70250917)
OSAME Mitsuhiro Kagoshima University, Graduate School of Medicine and Dental Sciences, Professor, 大学院・医歯学総合研究科, 教授 (10041435)
MARUYAMA Ikurou Kagoshima University, Graduate School of Medicine and Dental Sciences, Professor, 大学院・医歯学総合研究科, 教授 (20082282)
UMEHARA Fujio Kagoshima University, Graduate School of Medicine and Dental Sciences, Assistant Professor, 大学院・医歯学総合研究科, 講師 (20271140)
|
|---|
| Project Period (FY) |
1999 – 2002
|
| Keywords | Crow-Fukase syndrome / POEMS syndrome / VEGF / platelet / Transgenic mouse / transgenic mouse |
|---|
| Research Abstract |
We discovered that serum VEGF levels are markedly increased in Crow-Fukase syndrome. After having confirmed this finding along with other authors, we believe that the measurement of VEGF in the serum is a key marker for the diagnosis of Crow-Fukase syndrome. We found that most of the VEGF is stored in platelets, and VEGF is released after platelet aggregation in the peripheral circulation. Furthermore, platelet counts are high in this syndrome. High concentration of VEGF and an increased number of platelets magnify the physiological effect in the peripheral vessels, which then induce a hypercoagulable state (DIC). DIC is one of the most important factors in the prognosis of Crow-Fukase syndrome. Increased VEGF in the serum may predict DIC. We succeeded in establishing a transgenic mouse line in which VEGF will be over-expressed only in platelets, as is the case in patients with this syndrome. The detailed analysis of this transgenic mouse will clarify the pathogenesis and may establish the treatment strategy in this syndrome.
|
